182 related articles for article (PubMed ID: 36107220)
21. Effects of rifampicin on antineoplastic drug pyrotinib maleate pharmacokinetics in healthy subjects.
Cai MM; Dou T; Tang L; Sun QY; Zhai ZH; Wang HP; Qian W
Invest New Drugs; 2022 Aug; 40(4):756-761. PubMed ID: 35435627
[TBL] [Abstract][Full Text] [Related]
22. Influence of Rifampicin Pre-treatment on the In vivo Pharmacokinetics of Metoclopramide in Pakistani Healthy Volunteers Following Concurrent Oral Administration.
Kaukab I; Shah SNH; Abrar MA; Anwer N; Murtaza G
Curr Drug Metab; 2020; 21(4):301-306. PubMed ID: 32407272
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers.
Shaik MN; Hee B; Wei H; LaBadie RR
Br J Clin Pharmacol; 2018 Jun; 84(6):1346-1353. PubMed ID: 29488303
[TBL] [Abstract][Full Text] [Related]
24. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
[TBL] [Abstract][Full Text] [Related]
25. Clinical Drug-Drug Interaction Studies to Evaluate the Effects of a P-Glycoprotein Inhibitor, CYP3A Inhibitors, and a CYP3A Inducer on the Pharmacokinetics of Naldemedine in Healthy Subjects.
Fukumura K; Kawaguchi N; Ishibashi T; Kubota R; Tada Y; Ogura E
Clin Drug Investig; 2020 Jun; 40(6):529-540. PubMed ID: 32323104
[TBL] [Abstract][Full Text] [Related]
26. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects.
Abbas R; Boni J; Sonnichsen D
Drug Metab Pers Ther; 2015 Mar; 30(1):57-63. PubMed ID: 25803093
[TBL] [Abstract][Full Text] [Related]
27. Effect of rifampin on plasma concentrations of mefloquine in healthy volunteers.
Ridtitid W; Wongnawa M; Mahatthanatrakul W; Chaipol P; Sunbhanich M
J Pharm Pharmacol; 2000 Oct; 52(10):1265-9. PubMed ID: 11092571
[TBL] [Abstract][Full Text] [Related]
28. Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
Mu S; Tang Z; Novotny W; Tawashi M; Li TK; Ou Y; Sahasranaman S
Cancer Chemother Pharmacol; 2020 Feb; 85(2):391-399. PubMed ID: 31875923
[TBL] [Abstract][Full Text] [Related]
29. Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects.
Kirigaya Y; Shiramoto M; Ishizuka T; Uchimaru H; Irie S; Kato M; Shimizu T; Nakatsu T; Nishikawa Y; Ishizuka H
Br J Clin Pharmacol; 2020 Oct; 86(10):2070-2079. PubMed ID: 32250463
[TBL] [Abstract][Full Text] [Related]
30. Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor.
Li X; Shelton MJ; Wang J; Meade J; Ruiz-Soto R
Clin Pharmacol Drug Dev; 2022 Oct; 11(10):1165-1176. PubMed ID: 35560823
[TBL] [Abstract][Full Text] [Related]
31. Physiologically Based Pharmacokinetic Modeling for Maribavir to Inform Dosing in Drug-Drug Interaction Scenarios with CYP3A4 Inducers and Inhibitors.
Chen G; Sun K; Michon I; Barter Z; Neuhoff S; Ghosh L; Ilic K; Song IH
J Clin Pharmacol; 2024 May; 64(5):590-600. PubMed ID: 38009271
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of drug-drug interactions of pemigatinib in healthy participants.
Ji T; Rockich K; Epstein N; Overholt H; Wang P; Chen X; Punwani N; Yeleswaram S
Eur J Clin Pharmacol; 2021 Dec; 77(12):1887-1897. PubMed ID: 34282472
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects.
Gaudy A; Atsriku C; Ye Y; MacGorman K; Liu L; Xue Y; Surapaneni S; Palmisano M
Eur J Clin Pharmacol; 2021 Feb; 77(2):223-231. PubMed ID: 32965548
[TBL] [Abstract][Full Text] [Related]
34. Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis.
Gupta N; Hanley MJ; Venkatakrishnan K; Bessudo A; Rasco DW; Sharma S; O'Neil BH; Wang B; Liu G; Ke A; Patel C; Rowland Yeo K; Xia C; Zhang X; Esseltine DL; Nemunaitis J
J Clin Pharmacol; 2018 Feb; 58(2):180-192. PubMed ID: 28800141
[TBL] [Abstract][Full Text] [Related]
35. Effects of Quinidine or Rifampin Co-administration on the Single-Dose Pharmacokinetics and Safety of Rilzabrutinib (PRN1008) in Healthy Participants.
Rask-Madsen C; Katragadda S; Li M; Ucpinar S; Chinn L; Arora P; Smith P
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):590-600. PubMed ID: 38623935
[TBL] [Abstract][Full Text] [Related]
36. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
Ogasawara K; MacGorman K; Liu L; Chen J; Carayannopoulos LN; Zhou S; Palmisano M; Li Y
J Clin Pharmacol; 2019 Dec; 59(12):1620-1631. PubMed ID: 31172535
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Safety and Clinically Relevant Drug-Drug Interactions with Tucatinib in Healthy Volunteers.
Topletz-Erickson A; Lee A; Rustia EL; Sun H; Mayor JG; Abdulrasool LI; Walker L; Endres CJ
Clin Pharmacokinet; 2022 Oct; 61(10):1417-1426. PubMed ID: 35931943
[TBL] [Abstract][Full Text] [Related]
38. Phase I study to evaluate of the gastric pH-dependent drug interaction between famitinib and the proton pump inhibitor omeprazole in healthy subjects.
Hu L; Cai M; Qian W; Dou T; Sun Q; Tang L; Wang H
Invest New Drugs; 2022 Dec; 40(6):1274-1281. PubMed ID: 36087164
[TBL] [Abstract][Full Text] [Related]
39. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
Xu H; O'Gorman M; Tan W; Brega N; Bello A
Eur J Clin Pharmacol; 2015 Dec; 71(12):1441-9. PubMed ID: 26381275
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo.
Wang P; Liu J; Tan X; Yang F; McCabe J; Zhang J
Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):397-410. PubMed ID: 37357226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
